Traduction de «report and other » (Néerlandais → Français) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

As also discussed in notes 9 and 10 of the 2008 Annual Report, other intangible assets and investments in associated companies are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme le notent également les annexes 9 et 10 du Rapport annuel 2008, les autres immobilisations incorporelles et investissements dans des sociétés associées font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

The aim of proactive materiovigilance is to promote the reporting of incidents by users, among other means via an online reporting system
The aim of proactive materiovigilance is to promote the reporting of incidents by users, among other means via an online reporting system

In this science - policy advisory report, the Belgian Superior Health Council provides recommendations regarding infection control (Aspergillus and other mould, Legionella, etc) throughout a hospital design and construction project, as well as renovation works and other technical interventions carried out in health facilities; these recommendations are intended for the internal and external players involved in these activities.
In this science - policy advisory report, the Belgian Superior Health Council provides recommendations regarding infection control (Aspergillus and other mould, Legionella, etc) throughout a hospital design and construction project, as well as renovation works and other

Other decolonisation regimens have been described with limited success but can be an alternative: among others, topical decontamination with povidone-iodine 55 , tea tree oil 56 or nitrofurazone (Furacine®) have been reported successful 57,58 .
D'autres traitements de décolonisation ont été décrits avec un succès limité mais ils peuvent constituer une alternative: des décontaminations topiques avec de la povidone-iodine 54 , de l’huile d’arbre à thé 55 ou du nitrofurazone (Furacine®) 56,57 se sont avérées efficaces.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of October 21, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 21 octobre 2010.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of July 15, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 15 juillet 2010.

Report on the progress made in the use of biofuels and other renewable fuels in the Member States of the European Union 10/01/2007, COM (2006), 845 final.
Report on the progress made in the use of biofuels and other renewable fuels in the Member States of the European Union, 10/01/2007, COM (2006) 845 final.

3.3 Testing of other antibiotics for MRSA All MRSA isolates should be reported as resistant to all ß-lactam antibiotics, including ß-lactam/ ß- lactamase inhibitor combinations, cephalosporins and carbapenems.
3.3 Test d’autres antibiotiques pour MRSA Tous les isolats de MRSA doivent être rapportés comme résistants à tous les antibiotiques ß-lactame, en ce compris des combinaisons ß-lactame / inhibiteur de ß-lactamase, des céphalosporines et des carbapénèmes.

In the morning there is a plenary session (with, among other things, a witness report, a contribution by the Minister), in the afternoon there is a possibility of meeting fellow sufferers, taking part in workshops and conferences and taking a walk.
Cette journée consiste en une séance plénière le matin (avec entre autre un témoignage, une contribution du ministre…) et l’après-midi il y a la possibilité de rencontrer des compagnons d’infortune, et de participer à des ateliers, des conférences et une promenade.